drugset
drugset / Trial / NCT00455507

A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

NCT00455507 ↗

Phase 2 Completed 363 enrolled Kyowa Kirin, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa.

Timeline

Start
2007-03
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Istradefylline Small molecule 20 mg Oral
Subject Istradefylline Small molecule 40 mg Oral

Indications

Parkinson disease